leucine rich repeat and fibronectin type III domain containing 5Genealiases: C14orf146 · FIGLER8 · SALM5
Q-omics provides the consensus-scored LRFN5 profile across patient tissues and cancer cell-line models. LRFN5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LRFN5 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, LRFN5 RNA expression shows 19,465 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, BLCA, and GBM as cancer lineages where LRFN5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRFN5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRFN5 survival associations across molecular data types. LRFN5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRFN5 RNA expression–survival associations across cancer types. High LRFN5 expression shows unfavorable associations in UVM, LUSC and MESO, but favorable associations in BRCA, LGG and CHOL. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for LRFN5 RNA expression.
This table summarizes LRFN5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRFN5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRFN5 shows lower tumor expression in BLCA, THCA, COAD, UCEC and BRCA and higher tumor expression in KICH. The BLCA box plot shows higher LRFN5 RNA expression in normal versus tumor tissue (log2 FC = −3.125, t-test p < 0.001).
This table shows molecular features associated with LRFN5 in patient tissues and cancer cell lines. In patient samples, LRFN5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRFN5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
